Open access · CC-BY
via OpenAlex
Editorial: Restoring endoplasmic reticulum proteostasis to treat neurological disorders
Danilo B. Medinas, Najla Arshad, Sonam Parakh, Sayuri Miyamoto, Vanessa O. Zambelli
Frontiers in Pharmacology · 2023 · ▲ 1 citations
Loss of proteostasis
Mitochondrial dysfunction
Chronic inflammation
Rat
Human
Mouse
Preclinical / animal
Meta-analysis
Review
Abstract
Restoring endoplasmic reticulum proteostasis(definition) to treat neurological disorders A wide range of pathological conditions can affect normal functioning of the nervous system, constituting the second leading cause of death and the major factor for disability worldwide (Carroll, 2019). The etiology of neurological disorders is varied and complex, including genetic mutations, trauma, ischemia-reperfusion (IR) injury, aging, and many others. Most of these pathologies are incurable, meaning there is an urgent need for novel therapeutic strategies to sustain neuronal function and prevent cell death. Perturbations to proteostasis (i.e., protein homeostasis) of the nervous system have emerged as important pathogenic mechanisms contributing to protein aggregation, synaptic failure, neuroinflammation, among other disease hallmarks (Hetz, 2021). The endoplasmic reticulum (ER) is a major organelle involved in protein biogenesis, integrating many proteostasis pathways critical to cell migration and differentiation during neurodevelopment, in addition to maintenance and remodeling of the intricate neuronal morphology and synaptic connections over the organism's lifespan (Godin et al., 2016;Martínez et al., 2017Martínez et al., , 2018. In this Research Topic, we have gathered original and review manuscripts illustrating the potential of manipulating ER proteostasis to tackle neurological disorders.The interplay between proteostasis regulation and myriad cellular functions offers multiple points of intervention for therapeutic exploration. Studies in patients and experimental models established that ER proteostasis is compromised across several conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), stroke, among others (Hetz and Saxena, 2017). The proteostasis network in the ER has many components such as chaperones and folding catalysts, proteasomal and lysosomal degradation systems, and the unfolded protein response (UPR) that are disrupted in neurological disorders (Balch et al., 2008;Labbadia and Morimoto, 2015). Moreover, ER proteostasis also relies on the structural and functional integration of the ER with other organelles such as the mitochondria, in addition to being modulated by lipid metabolism (Wu et al., 2018). The growing mechanistic understanding of how these cellular systems are involved in the etiology of neurological conditions can provide the conceptual framework for the design of multimodal pharmacological interventions.In the review manuscript by Pérez-Arancibia et al, the authors provide a detailed discussion on the use of small molecules to treat neurological disorders, focusing mainly on PD and HD, the most common movement disorder caused by a dysfunction in the dopaminergic circuits. Molecules that have entered clinical trials are highlighted, which can be classified as synthetic or natural compounds. In addition, some emphasis is placed on drug repurposing and selected examples under preclinical testing, where the authors present mechanism of action of different compounds and critically discuss the challenges for their development into novel drugs. A common pathogenic event in neurodegenerative diseases like PD and HD is protein misfolding and aggregation, which can impact ER proteostasis at multiple levels (Hetz and Saxena, 2017). The studies discussed by Pérez-Arancibia et al clearly show that inhibiting the accumulation of misfolded and aggregated proteins holds great therapeutical promise by rescuing multiple cellular pathways intimately linked to ER proteostasis.A special feature of the nervous system is the structure afforded by the tight arrangement of endothelial cells of the vasculature along with glial cells and neurons, a system known as the blood brain barrier (BBB) or blood spinal cord barrier (BSCB) that shields against potentially toxic substances in the bloodstream. The BBB and BSCB also regulates the supply of nutrients and modulate the crosstalk between the nervous and immune systems, guaranteeing tissue homeostasis.The breakdown of the neurovascular unit has been associated to numerous neurodegenerative diseases and other pathological conditions marked by inflammatory response (Persidsky et al., 2006). In this context, Deng et al discuss the impairment of the BSCB under traumatic spinal cord injury (t-SCI), providing a meta-analysis of treatments that rescue BSCB in rat models of t-SCI. Excitingly, the authors have found that ER stress is a major contributor to BSCB damage, offering novel therapeutic targets. A common outcome of the experimental treatments examined by the authors is the upregulation of tight junction (TJ) and adhesion junction (AJ) proteins, which are an integral part of the BSCB, promoting close contacts between endothelial cells and regulating the nervous system permeability. Considering that TJ and AJ are constituted of membrane proteins produced in the ER, ER stress mitigation can lead to increased levels of TJ and AJ proteins and improved BSCB integrity.IR injury is another pathogenic insult that involves ER stress followed by neuronal demise.The original research contributed by Yuan et al describes the protective effects of AA147, a pharmacologic agonist of the activating transcription factor 6 (ATF6). ATF6 is a sensor and signal transducer of the UPR, which responds to ER stress by translocating the nucleus to promote adaptative gene expression programs to restore ER proteostasis. The authors show that AA147 treatment improved the neurological score of mice subjected to cardiac arrest followed by cardiopulmonary resuscitation. The beneficial effects of AA147 were accompanied by reduced apoptosis of neurons and diminished oxidative damage, in addition to increased levels of ER chaperones and antioxidant enzymes. Besides activating ATF6, AA147 also upregulates nuclear factor E2-related factor 2 (Nrf2), a major transcription factor inducing the antioxidant respo
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fphar.2023.1176805
- Canonical
- link ↗
- Fetched
- 2026-10-04 MST
Cite this
APA
Medinas, D.B., Arshad, N., Parakh, S., Miyamoto, S., & Zambelli, V.O. (2023). Editorial: Restoring endoplasmic reticulum proteostasis to treat neurological disorders. <em>Frontiers in Pharmacology</em>. https://doi.org/10.3389/fphar.2023.1176805
Vancouver
Medinas DB, Arshad N, Parakh S, Miyamoto S, Zambelli VO. Editorial: Restoring endoplasmic reticulum proteostasis to treat neurological disorders. Frontiers in Pharmacology. 2023. doi:10.3389/fphar.2023.1176805.
BibTeX
@article{danilo2023Editor,
title = {Editorial: Restoring endoplasmic reticulum proteostasis to treat neurological disorders},
author = {Danilo B. Medinas and Najla Arshad and Sonam Parakh and Sayuri Miyamoto and Vanessa O. Zambelli},
journal = {Frontiers in Pharmacology},
year = {2023},
doi = {10.3389/fphar.2023.1176805},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Molecular Neuroscience 2026
Open access · CC-BY
Editorial: Proteostasis disruption in neurodegenerative disorders: mechanisms and treatment strategies
Oxidative Medicine and Cellular Longevity 2020
Open access · CC-BY
Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress
Journal of Clinical Neurology 2023
Open access · CC-BY
Proteostasis and Ribostasis Impairment as Common Cell Death Mechanisms in Neurodegenerative Diseases
Philosophical Transactions of the Royal Society B Biological Sciences 2026
Open access · CC-BY
Proteostasis (in)action: the role of co-pathologies in neurodegenerative disease
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2026
Open access · OA
Proteostasis (in)action: the role of co-pathologies in neurodegenerative disease.
Frontiers in Aging Neuroscience 2020
Open access · CC-BY